Histological verification of the treatment effect of tirabrutinib for relapsed/refractory primary central nervous system lymphoma

Tirabrutinib (ONO/GS-4059; Ono Pharmaceutical) is a newly developed drug that selectively and irreversibly inhibits Bruton’s tyrosine kinase (BTK) and has been approved in Japan for treating relapsed/refractory primary central nervous system lymphoma (PCNSL). However, its therapeutic effect is yet t...

Descripción completa

Detalles Bibliográficos
Autores principales: Okita, Yoshiko, Kano-Fujiwara, Rieko, Nakatsuka, Shin-Ichi, Honma, Keiichiro, Kinoshita, Manabu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Letter to the Editor
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8077707/
https://www.ncbi.nlm.nih.gov/pubmed/33902692
http://dx.doi.org/10.1186/s40164-021-00222-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8077707/
https://www.ncbi.nlm.nih.gov/pubmed/33902692
http://dx.doi.org/10.1186/s40164-021-00222-5

Ejemplares similares